

Statistical Analysis 1 for Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment

Statistical Analysis Overview	Comparison Groups	ABT-450/r/ABT-267 and ABT-333, Plus RBV
	Comments	[Not specified]
	Non-Inferiority or Equivalence Analysis?	Yes
	Comments	Based on historical SVR rates for noncirrhotic pegIFN/RBV treatment-experienced subjects of the appropriate HCV genotype 1 subtype administered telaprevir plus pegIFN/RBV, the lower confidence bound (LCB) of the 95% confidence interval (CI) must have exceeded 77% to achieve superiority of the ABT-450/r/ABT-267 and ABT-333, plus RBV treatment group as compared with the historical rate for telaprevir plus pegIFN and RBV.
Method of Estimation	Estimation Parameter	Other [Percentage of Participants with SVR12]
	Estimated Value	96.7
	Confidence Interval	(2-Sided) 95% 93.6 to 99.9
	Estimation Comments	[Not specified]